Tag: rituximab
FDA accepts review of Dr. Reddy’s biosimilar rituximab candidate, DRL_RI
Dr. Reddy's Laboratories, an Indian pharmaceutical company, announced that the US Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for a ... Read More
Dr. Reddy’s Tocilizumab biosimilar shows promising results in phase 1 trial
Dr. Reddy's Laboratories, an Indian pharmaceutical company, announced a significant milestone as its tocilizumab biosimilar candidate, DRL_TC, successfully met primary and secondary endpoints in a ... Read More
BeiGene gets Brukinsa FDA approval for chronic lymphocytic leukemia
BeiGene has secured the approval of the US Food and Drug Administration (FDA) for the company’s Brukinsa (zanubrutinib) for the treatment of adult patients with ... Read More
Ipsen to acquire American biopharma company Epizyme for $247m
French pharma company Ipsen has agreed to acquire Epizyme, a Massachusetts-based commercial-stage biopharma company for an initial consideration of $247 million. Epizyme, which is listed ... Read More
Chronos-3 trial results : Aliqopa, rituximab combo meets primary endpoint of PFS, says Bayer
Chronos-3 trial results : Bayer said that the investigational combination of Aliqopa (copanlisib) and rituximab considerably increased progression-free survival (PFS) in patients having relapsed indolent ... Read More
Amgen, Allergan file BLA to FDA for Rituxan biosimilar ABP 798
Rituxan biosimilar ABP 798 : US biopharma company Amgen and Irish pharma company Allergan have submitted a Biologics License Application (BLA) to the US Food ... Read More
Pixuvri EMA approval : Servier NHL drug secures standard marketing authorization in Europe
Pixuvri EMA approval : French pharma company Servier has secured full approval for Pixuvri (pixantrone) from the European Commission (EC) as monotherapy for aggressive non-Hodgkin ... Read More
Nordic Nanovector initiates Betalutin rituximab combo trial in 2L FL
Nordic Nanovector has announced the dosing of the first patient in a phase 1b clinical trial called Archer-1 for evaluating the combination of its investigational ... Read More
FDA approves IMBRUVICA, rituximab combo for rare blood cancer
Janssen Pharmaceutical has bagged approval from the US Food and Drug Administration (FDA) for its combo of IMBRUVICA (ibrutinib) and rituximab for the treatment of ... Read More